A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma CANDOR Study of Carfilzomib ANd Daratumumab fOr Relapsed Myeloma

Trial Profile

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma CANDOR Study of Carfilzomib ANd Daratumumab fOr Relapsed Myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CANDOR
  • Sponsors Amgen
  • Most Recent Events

    • 20 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 20 Jun 2017 Planned End Date changed from 25 Jun 2022 to 23 Jun 2022.
    • 20 Jun 2017 Planned primary completion date changed from 9 Sep 2019 to 7 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top